Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Why Novartis Missed Wall Street Q1 Estimates

Novartis earnings and revenue came in below first-quarter estimates, with the Swiss drug giant guiding to modest 2021 growth. Novartis stock edged lower.

Novartis Earnings, Sales Slightly Miss First-Quarter Views

Bayer AG

A Milan judge on Tuesday indicted the Italian units of Novartis and Bayer on charges of operating a scheme to cheat the regional public health service in Lombardy, legal and judicial sources said.

Italy judge sends Bayer, Novartis to trial in drugs fraud probe: sources

Novartis AG (NYSE: NVS) Q1 core net income dropped 4% Y/Y, as COVID-19 related lockdowns and disruptions around the globe hit demand. Novartis missed earnings and sales expectations as the pandemic hit demand for drugs for breast cancer, skin and eye conditions.

Novartis Q1 Earnings Take A Hit Amid COVID-19 Impact

CureVac B.V

Novartis is scaling up facilities to make COVID-19 vaccine doses for German drugmaker CureVac and could boost production beyond levels agreed so far, Chief Executive Vas Narasimhan said on a conference call on Tuesday.

Novartis CEO says could boost CureVac vaccine production, if needed

Swiss drugmaker Novartis on Tuesday said first-quarter core net income fell 4%, missing analyst expectations, as COVID-19 related lockdowns and disruptions around the globe hit demand.

Novartis Q1 sales, profit miss analyst expectations amid COVID-19 impact

Basel, April 27, 2021 - commenting on the quarter, Vas Narasimhan, CEO of Novartis, said: “Novartis growth drivers and launches continued their strong momentum with double-digit growth for Entresto, Cosentyx, Oncology growth drivers and Zolgensma. We expect Sandoz performance to stabilize, in the near-term, after a challenging quarter. Our broad pipeline of novel medicines continued to progress, with the US approval of Entresto across the full spectrum of chronic heart failure and the positive readout for our radioligand therapy in prostate cancer. Our progress on building trust with society has been recognized by top rankings on the Access to Medicines Index and Sustainalytics. We remain confident in progressing our leading pipeline and delivering our growth outlook.”

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.

Roche Holding AG

Novartis (NVS) enters into an agreement with Roche for the manufacturing of the active pharmaceutical ingredient (API) for Actemra/RoActemra.

Novartis (NVS) Collaborates with Roche for API of RA Drug Actemra

Amazon

Alibaba

Salesforce

NIKE

These brand-name companies with $200 billion-plus market caps still have plenty of gas in the tank.

5 Megacap Stocks With 19% to 32% Upside, According to Wall Street

Novartis (NVS) enters a three-year collaboration with Artios to strengthen its radiogland therapies pipeline.

Novartis (NVS) Teams Up With Artios for Radioligand Therapies

Novartis AG (NYSE: NVS) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand therapies. Artios is set to get $20 million upfront and up to $1.3 billion in milestones in return for the targets.

Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio

BeiGene

Global X China Biotech Innovation ETF

Global X MSCI China Health Care ETF

KraneShares MSCI All China Health Care Index ETF

Healthcare was the second-best performing sector in China in 2020.

China Healthcare: A Rediscovered Sector Keeps Its Momentum

Just a week after acing Phase 3 study evaluating radioligand therapy in prostate cancer, Novartis AG (NYSE: NVS) is licensing the rights to develop and commercialize treatments based on a library of radioligand compounds from iTheranostics, a subsidiary of Sofie Biosciences. These compounds target fibroblast activation protein or FAP, a cell surface protein found in low levels in healthy tissue but found in high levels in common cancers.

Novartis Beefs Up Radioligand Portfolio With iTheranostics Deal

The European Commission approves Novartis' (NVS) Kesimpta for the treatment of adult patients with relapsing forms of multiple sclerosis.

Novartis (NVS) Gets EC Nod For Kesimpta in Relapsing Forms of MS

Johnson & Johnson

Johnson & Johnson's (NYSE:JNJ) 2020 revenue topped all pharmaceutical companies, according to rankings published by Fierce Pharma.

Johnson & Johnson, Roche and Novartis Top in Pharma Sales

Genmab - ADR

Novartis AG (NYSE: NVS) said that Kesimpta (ofatumumab) had won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis. The company is developing and marketing the product under a license agreement with Genmab A/S (NASDAQ: GMAB).

Novartis-Genmab's Kesimpta Gets EU Approval In Multiple Sclerosis

Basel, March 30, 2021 — Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc. The FAP assets were originally developed at the University of Heidelberg. The agreement also includes co-exclusive rights for Novartis to develop imaging applications for these assets.

Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

Shares in Valeo Pharma Inc (CSE:VPH) (OTCQB:VPHIF) (FRA:VP2) headed north on Monday as it struck a deal with Novartis Pharmaceuticals to commercialize two Health Canada approved asthma therapies. Under the agreement, Valeo will be responsible for medical and commercial activities for Enerzair Breezhaler and Atectura Breezhaler for an initial eight years, positioning it as one of the leading Canadian respiratory companies.

Valeo Pharma shares get a boost as it unveils deal with Novartis on two Health Canada approved asthma therapies

Novartis on Wednesday had to correct comments made by Chairman Joerg Reinhardt to a Swiss newspaper, because his portrayal of conduct that led to a $678 million U.S. settlement over kickbacks last year risked violating the agreement.

Novartis corrects chairman's comments about kickbacks case

Novartis (NVS) reports positive data from the phase III VISION study evaluating its radioligand therapy, 177Lu-PSMA-617, in patients with advanced prostate cancer.

Novartis (NVS) Posts Positive Data From Prostate Cancer Study

Novartis AG (NYSE: NVS) says that its Phase 3 VISION study of 177Lu-PSMA-617 hit both co-primary endpoints on overall survival and radiographic progression-free survival for prostate cancer patients. Details were not disclosed.

Novartis' Radioligand Therapy Hits Primary Endpoint Goal In Prostate Cancer Study

Basel, March, 23, 2021 — Novartis today reported the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard of care alone. The trial met both primary endpoints of overall survival and radiographic progression-free survival1, helping to move closer the ambition of becoming the targeted treatment for >80% of patients with advanced prostate cancer. The safety profile was consistent with data reported in previous clinical studies1. Results from the VISION trial will be presented at an upcoming medical meeting and included in US and EU regulatory submissions.

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer

Basel, March 22, 2021 — Novartis announced today the appointment of Karen L. Hale as Chief Legal Officer. She will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis (ECN), effective May 15, 2021. Ms. Hale will be based in Basel, Switzerland and succeeds Shannon Klinger. Tom Kendris will continue as Chief Legal Officer ad interim until Ms. Hale joins.

Novartis appoints Karen Hale as Chief Legal Officer

Snowflake

Digging into the popular investors' portfolios teaches us to look beyond Wall Street labels.

1 Stock Warren Buffett and Cathie Wood Have in Common and 1 They Should

Puma Biotechnology

Celcuity

Celcuity Inc (NASDAQ: CELC) has announced a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG (NYSE: NVS), and Puma Biotechnology Inc (NASDAQ: PUMA) to conduct a Phase 2 clinical trial. The open-label Phase 2 trial will evaluate the efficacy and safety of two targeted therapies, Novartis' Tabrecta, a c-Met inhibitor, and Puma's Nerlynx, a pan-HER inhibitor, in patients with previously treated metastatic HER2-negative breast cancer selected with Celcuity's CELsignia Multi-Pathway Activity Test.

Celcuity Teams Up With MD Anderson, Novartis, Puma Biotech To Study New Drug Regimen In Breast Cancer

News for Novartis Stock (NVS)